Medivir AB announced that the phase II study of MIV-711 in patients with osteoarthritis has been published in the respected journal Annals of Internal Medicine. The title of the article is "Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis", author; P.G Conaghan et al. Dr. Katz mentions the significant effect on changes in bone and cartilage degradation after six months of treatment with MIV-711, the high quality of Medivir's study data, as well as the likely need for longer treatment time to enable significant effect on pain.